BrainsWay Form 6-K notes first Deep TMS 360 trial initiative

Rhea-AI Filing Summary

BrainsWay Ltd. (BWAY) submitted a Form 6-K as a foreign private issuer, incorporating this report into its existing Form S-8 and Form F-3 registration statements filed in 2019, 2024, and 2025.

The report includes an exhibit titled “BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder.” This indicates that the company has begun its first clinical trial using the Deep TMS 360 system in the area of alcohol use disorder.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-35165

BRAINSWAY LTD.
(Translation of registrant's name into English)

16 Hartum Street RAD Tower, 14th Floor
Har HaHotzvim
Jerusalem, 9777516, Israel
(+972-2) 582-4030
 (Address and telephone number of Registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 22, 2019 (Registration No. 333- 230979) and the Company's Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 22, 2024 (Registration No. 333-280934) and on April 22, 2025 (Registration No. 333-286672).

EXHIBIT INDEX

Exhibit		Title
99.1		BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		BRAINSWAY LTD.
		(Registrant)
Date: November 17, 2025		/s/ Hadar Levy
		Hadar Levy
		Chief Executive Officer

FAQ

What did BrainsWay Ltd. (BWAY) report in this Form 6-K?

BrainsWay Ltd. filed a Form 6-K that is incorporated by reference into its existing Form S-8 and Form F-3 registration statements and includes an exhibit about a new clinical trial of its Deep TMS 360™ system for alcohol use disorder.

What is the key announcement in BrainsWay Ltd. (BWAY)'s exhibit 99.1?

Exhibit 99.1 is titled “BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder,” indicating the start of the first clinical trial of this system for that indication.

Which registration statements does this BrainsWay (BWAY) Form 6-K relate to?

The Form 6-K is incorporated by reference into BrainsWay's Form S-8 (Registration No. 333-230979) and its Form F-3 registration statements (Registration Nos. 333-280934 and 333-286672).

What type of issuer is BrainsWay Ltd. (BWAY) in this filing?

BrainsWay Ltd. is a foreign private issuer and indicates that it files annual reports under cover of Form 20-F.

Who signed the BrainsWay Ltd. (BWAY) Form 6-K and in what capacity?

The Form 6-K was signed by Hadar Levy, who is identified as the company's Chief Executive Officer.

What is the subject area of BrainsWay's new clinical trial mentioned in the Form 6-K?

The exhibit title states that the trial involves the Deep TMS 360™ system for alcohol use disorder.